ClearPoint Neuro stock surges on peer's FDA approval plan

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/26/2026

1. INTC
2. DECK
3. META
4. AMD
5. INFY
6. UNP
7. GOOGL
8. RNG
9. SPY
10. TMUS

Go back to ClearPoint Neuro stock surges on peer's FDA approval plan

Mizuho on uniQure BV (QURE): 'expressed confidence the overall signal — namely the slowing of disease progression — should remain directionally consistent'

June 17, 2026 1:27 PM EDT

Mizuho analyst Uy Ear reiterated an Outperform rating and $35.00 price target on uniQure BV (NASDAQ: QURE).

The analyst comments "FDA Under New Leadership Seems to Signal Renewed Flexibility in Rare Diseases: Regarding the Type B meeting, management noted the core review team remained largely unchanged, but leadership-level discussions seem to have enabled a more pragmatic path forward, which led to the agency's willingness to find the 3-year Phase I/II results as supportive of an Accelerated BLA filing and non-sham control confirmatory Phase 3 trial. Management highlighted a constructive shift in tone following recent... More

uniQure BV (QURE) PT Raised to $71 at Stifel

June 17, 2026 9:31 AM EDT

Stifel analyst Paul Matteis raised the price target on uniQure BV (NASDAQ: QURE) to $71.00 (from $28.00) while maintaining a Buy rating.

The analyst comments "We're reiterating our Buy rating on QURE and raising our TP to $71, on the back of a positive and welcome surprise around FDA's ~180 on the regulatory path for AMT-130 (LINK). Bottom line: we now model a slightly greater than 50%... More